Could a Mitochondria-Boosting drug help save sight in glaucoma?
NCT ID NCT06437639
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 4 trial tested the drug Mexidol in 80 people with advanced primary open-angle glaucoma. The goal was to see if the drug could improve the function of mitochondria in cells and protect the optic nerve. Participants were randomly assigned to receive Mexidol or standard care, and researchers measured changes in cell energy levels and vision over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mexidol (ethylmethylhydroxypyridine succinate)
What this could lead to
If it works, this could point toward a way to protect the optic nerve in glaucoma patients, potentially slowing vision loss.
What could go wrong
This is a small, completed Phase 4 trial with only 80 participants, so results may not apply to everyone. The main focus is on cell-level changes, not direct vision improvement, and the drug may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tyumen Scientific Center of the Russian Academy of Sciences
Tyumen, Russian Federation, 625026, Russia